Friday, February 21, 2020 Daily Archives

Another WuXi Vaccines deal? No, just a repurposed press release

by

Contrary to some reports, WuXi Biologics is not building a second facility for its recently formed vaccines joint venture but has merely secured the $3 billion contract announced last May. Nine months ago, WuXi Biologics and Shanghai-based Hile Bio-Technology formed WuXi Vaccines, a contract development and manufacturing organization (CDMO) to service a Letter of Intent (LOI) inked with an undisclosed multinational vaccine company. In November, plans were laid to build a $240 million (€222 million) three-story dedicated manufacturing facility in…

February 21, 2020

Orgenesis teams with Johns Hopkins’ in first post Masthercell sale PoC deal

by

Johns Hopkins University will use Orgenesis’ point-of-care processing technology for cell and gene therapy research in a collaboration announced this week. The US research University has licensed access to Orgenesis’s ‘point-of-care’ (PoC) platform which – as the name suggests – is used to develop and process cell therapies in the clinic Orgenesis CEO Vered Caplan said, “Our POCare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed…

February 21, 2020